| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA383563
Max Phase: Preclinical
Molecular Formula: C15H13NO2
Molecular Weight: 239.27
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: Nc1ccc(C(=O)/C=C/c2ccc(O)cc2)cc1
Standard InChI: InChI=1S/C15H13NO2/c16-13-6-4-12(5-7-13)15(18)10-3-11-1-8-14(17)9-2-11/h1-10,17H,16H2/b10-3+
Standard InChI Key: GJKSOGFGWQZGRL-XCVCLJGOSA-N
Associated Targets(Human)
TM4SF5 Tbio Transmembrane 4 L6 family member 5 (74 Activities)
Associated Targets(non-human)
amyS Alpha-amylase (22 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
BMY1 Beta-amylase (20 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
PPO2 Tyrosinase (3884 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
B16 (5829 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Toxoplasma gondii (4585 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 239.27 | Molecular Weight (Monoisotopic): 239.0946 | AlogP: 2.87 | #Rotatable Bonds: 3 |
| Polar Surface Area: 63.32 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 9.04 | CX Basic pKa: 3.11 | CX LogP: 2.76 | CX LogD: 2.75 |
| Aromatic Rings: 2 | Heavy Atoms: 18 | QED Weighted: 0.49 | Np Likeness Score: 0.29 |
References
| 1. Seo WD, Kim JH, Kang JE, Ryu HW, Curtis-Long MJ, Lee HS, Yang MS, Park KH.. (2005) Sulfonamide chalcone as a new class of alpha-glucosidase inhibitors., 15 (24): [PMID:16202584] [10.1016/j.bmcl.2005.08.087] |
| 2. Seo WD, Ryu YB, Curtis-Long MJ, Lee CW, Ryu HW, Jang KC, Park KH.. (2010) Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone., 45 (5): [PMID:20149498] [10.1016/j.ejmech.2010.01.049] |
| 3. (2013) Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds, |
| 4. Jiang L, Liu B, Hou S, Su T, Fan Q, Alyafeai E, Tang Y, Wu M, Liu X, Li J, Hu Y, Li W, Zheng Z, Liu Y, Wu J.. (2022) Discovery and evaluation of chalcone derivatives as novel potential anti-Toxoplasma gondii agents., 234 [PMID:35278752] [10.1016/j.ejmech.2022.114244] |
Source
Source(2):